Show simple item record

dc.contributor.authorMueller, Yolanda K
dc.contributor.authorKolaczinski, Jan H
dc.contributor.authorKoech, Timothy
dc.contributor.authorLokwang, Peter
dc.contributor.authorRiongoita, Mark
dc.contributor.authorVelilla, Elena
dc.contributor.authorBrooker, Simon J
dc.contributor.authorChappuis, François
dc.date.accessioned2014-01-21T20:03:03Z
dc.date.available2014-01-21T20:03:03Z
dc.date.issued2013-11-11
dc.identifier.citationClinical Epidemiology, Diagnosis and Treatment of Visceral Leishmaniasis in the Pokot Endemic Area of Uganda and Kenya. 2013: Am. J. Trop. Med. Hyg.en_GB
dc.identifier.issn1476-1645
dc.identifier.pmid24218406
dc.identifier.doi10.4269/ajtmh.13-0150
dc.identifier.urihttp://hdl.handle.net/10144/311672
dc.description.abstractBetween 2000 and 2010, Médecins Sans Frontières diagnosed and treated 4,831 patients with visceral leishmaniasis (VL) in the Pokot region straddling the border between Uganda and Kenya. A retrospective analysis of routinely collected clinical data showed no marked seasonal or annual fluctuations. Males between 5 and 14 years of age were the most affected group. Marked splenomegaly and anemia were striking features. An Rk39 antigen-based rapid diagnostic test was evaluated and found sufficiently accurate to replace the direct agglutination test and spleen aspiration as the first-line diagnostic procedure. The case-fatality rate with sodium stibogluconate as first-line treatment was low. The VL relapses were rare and often diagnosed more than 6 months post-treatment. Post-kala-azar dermal leishmaniasis was rare but likely to be underdiagnosed. The epidemiological and clinical features of VL in the Pokot area differed markedly from VL in Sudan, the main endemic focus in Africa.
dc.languageENG
dc.language.isoenen
dc.relation.urlhttp://www.ajtmh.orgen_GB
dc.rightsArchived with thanks to The American Journal of Tropical Medicine and Hygieneen_GB
dc.subjectKala Azar/Visceral Leishmaniasisen_GB
dc.titleClinical Epidemiology, Diagnosis and Treatment of Visceral Leishmaniasis in the Pokot Endemic Area of Uganda and Kenyaen
dc.contributor.departmentEpicentre, Paris, France; Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom; Médecins Sans Frontières, Operational Centre, Geneva, Switzerland; Geneva University Hospitals and University of Geneva, Geneva, Switzerland.en_GB
dc.identifier.journalThe American Journal of Tropical Medicine and Hygieneen_GB
refterms.dateFOA2019-03-04T11:03:40Z
html.description.abstractBetween 2000 and 2010, Médecins Sans Frontières diagnosed and treated 4,831 patients with visceral leishmaniasis (VL) in the Pokot region straddling the border between Uganda and Kenya. A retrospective analysis of routinely collected clinical data showed no marked seasonal or annual fluctuations. Males between 5 and 14 years of age were the most affected group. Marked splenomegaly and anemia were striking features. An Rk39 antigen-based rapid diagnostic test was evaluated and found sufficiently accurate to replace the direct agglutination test and spleen aspiration as the first-line diagnostic procedure. The case-fatality rate with sodium stibogluconate as first-line treatment was low. The VL relapses were rare and often diagnosed more than 6 months post-treatment. Post-kala-azar dermal leishmaniasis was rare but likely to be underdiagnosed. The epidemiological and clinical features of VL in the Pokot area differed markedly from VL in Sudan, the main endemic focus in Africa.


Files in this item

Thumbnail
Name:
Mueller et al-2013-Clinical ...
Size:
5.405Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record